{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:22Z","timestamp":1788931222480,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Several immune checkpoint inhibitors have been implemented for cancer treatment which have shown some degree of antitumor effcacy, while immune-related adverse events (irAEs) that affect multiple organ functions ensue which obviously should not be neglected. Though less common than other kinds of irAEs, Immune checkpoint inhibitors (ICIs) related Isolated ACTH deficiency (IAD) may cause long-term damage to pituitary-adrenal axis. Several case reports are available about IAD during anti-PD-1 therapy. We report the first case of immune checkpoint inhibitor-induced IAD following 3\u00a0month of sintilimab therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 66-year-old Chinese man was diagnosed with stage IIIB lung adenocarcinoma with involving ipsilateral intrapulmonary and hilar lymph node metastasis. After 3\u00a0months of combination therapy of nedaplatin, pemetrexed and sintilimab, the patient presented with general fatigue, nausea and vomiting. Laboratory investigation at admission revealed hyponatremia and hypokalemia. Further investigation revealed adrenocorticotropic hormone and cortisol levels were far below than normal limits. His other pituitary hormone levels were normal, except for mild elevation of follicle stimulating hormone and estradiol. Cranic magnetic resonance imaging showed a normal pituitary gland. Isolated adrenocorticotropic hormone deficiency was diagnosed, and corticosteroid replacement therapy was administered, leading to a significant improvement of his symptoms while ACTH level maintaining low level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our patient developed isolated ACTH deficiency during combination cancer treatment with chemotherapy and sintilimab. Although isolated ACTH deficiency due to anti-PD-1 including sintilimab therapy is rare occurrence, it can often cause severe clinical symptoms. Its diagnosis basically relies on clinical symptoms and endocrinological examination. Unlike traditional hypophysitis diagnosed by cranial MRI, pituitary MRI of IAD due to anti-PD-1 often indicates normal pituitary gland implying that over-reliance on imaging findings is not recommended. Even if clinical symptoms have relieved after corticosteroid replacement therapy was commenced, low levels of ACTH or cortisol could maintain for a long period which highlights the need for long term corticosteroid therapy. The purpose of the current report was to provide increased awareness of early detection and therapy of IAD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01151-y","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T20:38:38Z","timestamp":1664051918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review"],"prefix":"10.1186","volume":"22","author":[{"given":"Si-Hong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-7067","authenticated-orcid":false,"given":"Can-Tu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"issue":"7","key":"1151_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","volume":"20","author":"GK Pennock","year":"2015","unstructured":"Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20(7):812\u201322. https:\/\/doi.org\/10.1634\/theoncologist.2014-0422.","journal-title":"Oncologist"},{"key":"1151_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016 (Epub 2016 Jan 5. PMID: 26765102).","journal-title":"Eur J Cancer"},{"issue":"1","key":"1151_CR3","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y (Published 2020 Jul 30).","journal-title":"Nat Commun"},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70\u20136. https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002 (Epub 2017 Jun 22. PMID: 28689073).","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1151_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J Immunother Cancer. 2019;7(1):286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2 (Published 2019 Nov 6).","journal-title":"J Immunother Cancer"},{"key":"1151_CR6","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020;10:594558. https:\/\/doi.org\/10.3389\/fonc.2020.594558 (Published 2020 Nov 26).","journal-title":"Front Oncol"},{"issue":"2","key":"1151_CR7","doi-asserted-by":"publisher","first-page":"102454","DOI":"10.1016\/j.autrev.2019.102454","volume":"19","author":"R Percik","year":"2020","unstructured":"Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, Greenberg G, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T. Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2020;19(2):102454. https:\/\/doi.org\/10.1016\/j.autrev.2019.102454 (Epub 2019 Dec 12. PMID: 31838158).","journal-title":"Autoimmun Rev"},{"issue":"18","key":"1151_CR8","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706\u201314. https:\/\/doi.org\/10.1002\/cncr.31629 (Epub 2018 Jul 5. PMID: 29975414).","journal-title":"Cancer"},{"issue":"3","key":"1151_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Sintilimab: First Global Approval. Drugs. 2019;79(3):341\u20136. https:\/\/doi.org\/10.1007\/s40265-019-1066-z (PMID: 30742278).","journal-title":"Drugs"},{"issue":"1","key":"1151_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","volume":"8","author":"X Liu","year":"2020","unstructured":"Liu X, Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res. 2020;8(1):69. https:\/\/doi.org\/10.1186\/s40364-020-00250-z (Published 2020 Nov 26).","journal-title":"Biomark Res"},{"issue":"1","key":"1151_CR11","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12\u20139. https:\/\/doi.org\/10.1016\/S2352-3026(18)30192-3 (PMID: 30612710).","journal-title":"Lancet Haematol"},{"issue":"5","key":"1151_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816\u201326. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.017 (Epub 2020 Feb 6. PMID: 32036071).","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1151_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","volume":"24","author":"P Iglesias","year":"2021","unstructured":"Iglesias P, S\u00e1nchez JC, D\u00edez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021;24(4):630\u201343. https:\/\/doi.org\/10.1007\/s11102-021-01141-8 (Epub 2021 Mar 24. PMID: 33761049).","journal-title":"Pituitary"},{"issue":"5","key":"1151_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.21037\/atm-21-7006","volume":"10","author":"K Cui","year":"2022","unstructured":"Cui K, Wang Z, Zhang Q, Zhang X. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study. Ann Transl Med. 2022;10(5):251. https:\/\/doi.org\/10.21037\/atm-21-7006 (PMID:35402601;PMCID:PMC8987884).","journal-title":"Ann Transl Med"},{"issue":"3","key":"1151_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181(3):211\u20139. https:\/\/doi.org\/10.1530\/EJE-19-0238 (PMID: 31176301).","journal-title":"Eur J Endocrinol"},{"issue":"26","key":"1151_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.rmcr.2019.01.021","volume":"28","author":"Y Sato","year":"2019","unstructured":"Sato Y, Tanaka Y, Hino M, Seike M, Gemma A. A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. Respir Med Case Rep. 2019;28(26):223\u20136. https:\/\/doi.org\/10.1016\/j.rmcr.2019.01.021 (PMID:30740300;PMCID:PMC6356048).","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"1151_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/mco.2018.1781","volume":"10","author":"N Furubayashi","year":"2019","unstructured":"Furubayashi N, Negishi T, Uozumi T, Takamatsu D, Shiraishi K, Hirose D, Nakamura M. Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. Mol Clin Oncol. 2019;10(2):304\u20138. https:\/\/doi.org\/10.3892\/mco.2018.1781 (Epub 2018 Nov 30. PMID: 30680212; PMCID: PMC6327214).","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"1151_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyx018","volume":"47","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, Furue M, Nomura M. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol. 2017;47(5):463\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyx018 (PMID: 28334791).","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"1151_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2340\/00015555-2902","volume":"98","author":"S Kitano","year":"2018","unstructured":"Kitano S, Tatsuno K, Ishibe J, Shimauchi T, Fujiyama T, Ito T, Ogawa N, Tokura Y. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab. Acta Derm Venereol. 2018;98(7):704\u20135. https:\/\/doi.org\/10.2340\/00015555-2902 (PMID: 29405244).","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1151_CR20","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.13571","volume":"44","author":"A Narahira","year":"2017","unstructured":"Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol. 2017;44(4):e70. https:\/\/doi.org\/10.1111\/1346-8138.13571 (Epub 2016 Sep 8. PMID: 27608187).","journal-title":"J Dermatol."},{"issue":"18","key":"1151_CR21","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","volume":"56","author":"K Takaya","year":"2017","unstructured":"Takaya K, Sonoda M, Fuchigami A, Hiyoshi T. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med. 2017;56(18):2463\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.8548-16 (Epub 2017 Aug 21. PMID: 28824067; PMCID: PMC5643175).","journal-title":"Intern Med."},{"issue":"6","key":"1151_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.anl.2019.02.005","volume":"46","author":"K Hihara","year":"2019","unstructured":"Hihara K, Sato H, Okamoto I, Katsube Y, Maruyama R, Tomioka R, Tanaka H, Tsukahara K. Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer. Auris Nasus Larynx. 2019;46(6):896\u2013901. https:\/\/doi.org\/10.1016\/j.anl.2019.02.005 (Epub 2019 Jul 23. PMID: 31350019).","journal-title":"Auris Nasus Larynx"},{"issue":"4","key":"1151_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","volume":"57","author":"N Ohara","year":"2018","unstructured":"Ohara N, Ohashi K, Fujisaki T, et al. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. Intern Med. 2018;57(4):527\u201335. https:\/\/doi.org\/10.2169\/internalmedicine.9074-17.","journal-title":"Intern Med"},{"issue":"2","key":"1151_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","volume":"47","author":"H Kagoshima","year":"2020","unstructured":"Kagoshima H, Hori R, Kojima T, Okanoue Y, Fujimura S, Taguchi A, Shoji K. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer. Auris Nasus Larynx. 2020;47(2):309\u201313. https:\/\/doi.org\/10.1016\/j.anl.2019.05.009 (Epub 2019 Jun 22. PMID: 31235078).","journal-title":"Auris Nasus Larynx"},{"issue":"3","key":"1151_CR25","first-page":"115","volume":"42","author":"T Seki","year":"2017","unstructured":"Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. Tokai J Exp Clin Med. 2017;42(3):115\u201320 (PMID: 28871578).","journal-title":"Tokai J Exp Clin Med"},{"issue":"4","key":"1151_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.14740\/jocmr3257w","volume":"10","author":"K Takebayashi","year":"2018","unstructured":"Takebayashi K, Ujiie A, Kubo M, Furukawa S, Yamauchi M, Shinozaki H, Suzuki T, Naruse R, Hara K, Tsuchiya T, Inukai T. Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. J Clin Med Res. 2018;10(4):358\u201362. https:\/\/doi.org\/10.14740\/jocmr3257w (Epub 2018 Feb 18. PMID: 29511426; PMCID: PMC5827922).","journal-title":"J Clin Med Res"},{"issue":"4","key":"1151_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","volume":"66","author":"S Okahata","year":"2019","unstructured":"Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Noso S, Ikegami H, Shiba T. Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. Endocr J. 2019;66(4):295\u2013300. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0328 (Epub 2019 Feb 27. PMID: 30814440).","journal-title":"Endocr J"},{"issue":"8","key":"1151_CR28","doi-asserted-by":"publisher","first-page":"e230848","DOI":"10.1136\/bcr-2019-230848","volume":"12","author":"J Pierrard","year":"2019","unstructured":"Pierrard J, Petit B, Lejeune S, Seront E. Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab. BMJ Case Rep. 2019;12(8):e230848. https:\/\/doi.org\/10.1136\/bcr-2019-230848 (PMID:31439558;PMCID:PMC6720815).","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1151_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000505687","volume":"13","author":"T Bekki","year":"2020","unstructured":"Bekki T, Takakura Y, Kochi M, Konemori Y, Oki K, Yoneda M, Egi H, Ohdan H. A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab. Case Rep Oncol. 2020;13(1):200\u20136. https:\/\/doi.org\/10.1159\/000505687 (PMID:32308578;PMCID:PMC7154275).","journal-title":"Case Rep Oncol"},{"issue":"6","key":"1151_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-019-0092-9","volume":"6","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Kushimoto M, Nishizawa T, Takubo M, Mitsuke K, Ikeda J, Fujishiro M, Ogawa K, Tsujino I, Suzuki Y, Abe M. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Clin Diabetes Endocrinol. 2020;6(6):1. https:\/\/doi.org\/10.1186\/s40842-019-0092-9 (PMID:31921440;PMCID:PMC6945618).","journal-title":"Clin Diabetes Endocrinol"},{"issue":"24","key":"1151_CR31","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.2169\/internalmedicine.3008-19","volume":"58","author":"S Yamagata","year":"2019","unstructured":"Yamagata S, Kageyama K, Takayasu S, Asari Y, Makita K, Terui K, Daimon M. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Intern Med. 2019;58(24):3557\u201362. https:\/\/doi.org\/10.2169\/internalmedicine.3008-19 (Epub 2019 Aug 28. PMID: 31462588; PMCID: PMC6949454).","journal-title":"Intern Med"},{"issue":"3","key":"1151_CR32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.13532","volume":"44","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017;44(3):e13\u20134. https:\/\/doi.org\/10.1111\/1346-8138.13532 (Epub 2016 Jul 21 PMID: 27440178).","journal-title":"J Dermatol"},{"key":"1151_CR33","doi-asserted-by":"publisher","first-page":"bcr2018225048","DOI":"10.1136\/bcr-2018-225048","volume":"2018","author":"S Shrotriya","year":"2018","unstructured":"Shrotriya S, Rai MP, Alratroot A, Sarzynski E. Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). BMJ Case Rep. 2018;2018:bcr2018225048. https:\/\/doi.org\/10.1136\/bcr-2018-225048 (PMID: 30093497; PMCID: PMC6088290).","journal-title":"BMJ Case Rep"},{"issue":"19","key":"1151_CR34","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609 (Epub 2010 Jun 1. PMID: 20516446; PMCID: PMC4834717).","journal-title":"J Clin Oncol"},{"issue":"2","key":"1151_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]. Endocr J. 2017;64(2):235\u20136. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0596 (Epub 2017 Jan 6. PMID: 28070057).","journal-title":"Endocr J"},{"issue":"8","key":"1151_CR36","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.21873\/anticanres.11814","volume":"37","author":"R Ariyasu","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M. Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. Anticancer Res. 2017;37(8):4229\u201332. https:\/\/doi.org\/10.21873\/anticanres.11814 (PMID: 28739711).","journal-title":"Anticancer Res"},{"issue":"8","key":"1151_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","volume":"7","author":"P Caturegli","year":"2008","unstructured":"Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR. Pituitary autoimmunity: 30 years later. Autoimmun Rev. 2008;7(8):631\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2008.04.016 (Epub 2008 May 8. PMID: 18774118; PMCID: PMC3383826).","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1151_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82\u201392. https:\/\/doi.org\/10.1007\/s11102-015-0671-4 (PMID: 26186958).","journal-title":"Pituitary"},{"issue":"3","key":"1151_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2018.02.011","volume":"40","author":"C Johnson","year":"2018","unstructured":"Johnson C, Jazaeri AA. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther. 2018;40(3):389\u201394. https:\/\/doi.org\/10.1016\/j.clinthera.2018.02.011 (Epub 2018 Mar 5. PMID: 29519715).","journal-title":"Clin Ther"},{"issue":"2","key":"1151_CR40","doi-asserted-by":"publisher","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","volume":"8","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020;8(2):e000779.\u00a0\u00a0https:\/\/doi.org\/10.1136\/jitc-2020-000779. PMID:32606047;PMCID:PMC7328763","journal-title":"J Immunother Cancer"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01151-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T20:41:01Z","timestamp":1664052061000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01151-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01151-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the journal editor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}